Impact of a national external quality assessment scheme for breast pathology in the UK
about
Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.Assessing agreement between multiple raters with missing rating information, applied to breast cancer tumour grading.A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trialBreast cancer prognostic classification in the molecular era: the role of histological grade.Increased alpha-fetoprotein receptor in the serum of patients with early-stage breast cancer.The NHS breast screening programme (pathology) EQA: experience in recent years relating to issues involved in individual performance appraisal.Ductal carcinoma in situ: recent advances and future prospects.Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancerMaximising benefit and minimising harm of screening.Practical implications of gene-expression-based assays for breast oncologists.Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network.Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation.The classification of invasive carcinoma of the breast.Changes in breast cancer reports after pathology second opinion.Ductal carcinoma in situ - update on risk assessment and management.Characteristics associated with requests by pathologists for second opinions on breast biopsies.Review of the national external quality assessment (EQA) scheme for breast pathology in the UK.Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme.Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.Molecular and clinicopathological markers of prognosis in breast cancer.Papillary carcinoma of the breast: diagnostic agreement and management implications.Evaluation of the use of digital images for a national prostate core external quality assurance scheme.Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers.Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens.
P2860
Q30318823-549431FD-9BF3-4460-B302-8E5077877995Q33359537-7C353927-476F-4F7C-9674-A09FF8562957Q34000255-A6DC9C85-3812-48EC-9D55-F780392B5F40Q34173440-05E50A7F-442F-4A24-8028-4851B9391F25Q35703590-65955373-3147-49F2-BFA8-DC6C3F135165Q35769673-5A385D77-63BC-48E7-959B-0F6DD577E8D7Q35996817-D423BCB3-44A5-4D44-86C1-9F3AC4DCA807Q36393082-83174096-661B-4500-9CFD-B34167C9C264Q36482925-92C476FD-AB16-4AE6-BE30-74E9A62050D1Q36989546-E6E56D2F-8C8E-4A03-BDFD-06DF9B8F1E23Q37417169-1798803F-54D6-44CD-9BF5-22063D486981Q37740955-D0A5B361-02FD-4D65-A703-62C4C0ECC4F0Q38132239-C7DB0A04-A3EF-4A74-BC94-10C6ACB4FA18Q38201141-A4186FB1-C449-49BD-858F-7F6F1D358239Q38696796-986F0C36-970F-4779-9491-6A8F2FFD5557Q38808016-83899C54-F20A-4717-B7C5-0A8ABE00AC48Q38894293-3AF7CCA4-445A-40C8-9FB2-A73BFC6033FCQ39060237-9210B740-C64D-4B2E-91EE-6879FA18FC8AQ39263199-93264940-B1A0-45A0-8FCC-42B52126101DQ39267625-997C986A-8634-444F-9928-8C0E410E0AFCQ39399933-8AE8CB1C-09DF-4A4D-A59A-877443A02D47Q39704256-0F9983E0-0A29-4CEB-AEA9-541204BE4B28Q40003674-2DF01E70-393F-42CF-8B7E-D08DEA0D87C2Q40348121-CB909D92-A2BE-45DD-9972-FE0290FF7CA1Q46699535-4C4BC3BE-904A-41B0-8179-92CC4E0B1159Q51766497-869BECDF-6A0B-4060-AEA9-19B0ACE41F95Q53220568-AF7EB748-762B-421D-A142-59841C57E7A8
P2860
Impact of a national external quality assessment scheme for breast pathology in the UK
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Impact of a national external quality assessment scheme for breast pathology in the UK
@ast
Impact of a national external quality assessment scheme for breast pathology in the UK
@en
Impact of a national external quality assessment scheme for breast pathology in the UK
@en-gb
type
label
Impact of a national external quality assessment scheme for breast pathology in the UK
@ast
Impact of a national external quality assessment scheme for breast pathology in the UK
@en
Impact of a national external quality assessment scheme for breast pathology in the UK
@en-gb
prefLabel
Impact of a national external quality assessment scheme for breast pathology in the UK
@ast
Impact of a national external quality assessment scheme for breast pathology in the UK
@en
Impact of a national external quality assessment scheme for breast pathology in the UK
@en-gb
P2093
P2860
P50
P356
P1476
Impact of a national external quality assessment scheme for breast pathology in the UK
@en
P2093
A J Robertson
C E Connolly
P2860
P304
P356
10.1136/JCP.2004.025551
P407
P577
2006-02-01T00:00:00Z